%0 Journal Article
%T The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis
%A Xiaoshun Shi
%A Fuxi Huang
%A Allen M. Chen
%A Zhuolin Wu
%A Qianqian Huang
%A Ying Liang
%A Qipeng Zhou
%A Haiyun Mo
%A Xiaoxiang Li
%A Jiexia Zhang
%J Open Journal of Genetics
%P 117-129
%@ 2162-4461
%D 2017
%I Scientific Research Publishing
%R 10.4236/ojgen.2017.74010
%X <span style=\"font-family:Verdana;\"><strong>Background:</strong></span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\"> Emerging evidence indicates that chemotherapy for lung cancer may alter
EGFR mutation status. However, whether chemotherapy as a firstline treatment
may increase or reduce the frequency of EGFR mutations in NSCLC remains
uncertain. Therefore, we conducted a meta-analysis to evaluate whether
chemotherapy leads to altered EGFR mutation status. </span><b><span style=\"font-family:Verdana;\">Methods:</span></b><span style=\"font-family:Verdana;\"> A
systematic literature search was performed using the PubMed, OVID, Science Direct,
Cochrane Library, and CNKI databases for studies on pre- and </span><span style=\"font-family:Verdana;\">post-chemotherapy EGFR mutation status. Relevant
studies documenting peri</span><span style=\"font-family:Verdana;\">chemotherapy EGFR mutation ratios were
included. Analyses of pooled odds ratios (OR) were performed. </span><b><span style=\"font-family:Verdana;\">Results:</span></b><span style=\"font-family:Verdana;\"> Six studies involving 656 patients were included in this meta-analysis. It was
found that chemotherapy may alter EGFR status (OR = 1.93, 95% CI 1.05 - 3.56; p
&lt; 0.0001). No significant differences in EGFR mutation alterations were
observed in terms of gender, smoking history, EGFR loci, or chemotherapy
response in NSCLC patients. </span><b><span style=\"font-family:Verdana;\">Conclusions:</span></b><span style=\"font-family:Verdana;\"> Chemotherapy may contribute to
altered EGFR status. NSCLC patients with EGFR mutations might need to be
considered for EGFR status redeterminations prior to second-line EGFR-TKI
treatment or upon tumor recurrence after chemotherapy. Further randomized
clinical trials should investigate the impact of neoadjuvant or first-line
chemotherapy on EGFR mutation status in NSCLC patients.</span></span>
%K EGFR Mutation
%K Chemotherapy
%K Non-Small Cell Lung Cancer
%K Me-ta-Analysis
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=81209